Haemonetics Operating Cycle from 2010 to 2026
| HAE Stock | USD 57.64 0.14 0.24% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 251.483835 | Current Value 176.12 | Quarterly Volatility 26.63384271 |
Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 13.7 M, Total Revenue of 1.6 B or Gross Profit of 940.1 M, as well as many indicators such as Price To Sales Ratio of 2.14, Dividend Yield of 0.0098 or PTB Ratio of 2.81. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
Haemonetics | Operating Cycle | Build AI portfolio with Haemonetics Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out the analysis of Haemonetics Correlation against competitors. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.